- Home
- LYEL vs NRC Comparison
LYEL vs NRC Comparison
Compare LYEL & NRC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LYEL | NRC |
|---|---|---|
| Founded | 2018 | 1981 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 490.1M | 428.2M |
| IPO Year | 2021 | 1997 |
Fundamental Metrics
Financial Performance| Metric | LYEL | NRC |
|---|---|---|
| Price | $19.89 | $17.00 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $27.25 | N/A |
| AVG Volume (30 Days) | 83.6K | ★ 102.1K |
| Earning Date | 03-12-2026 | 04-27-2026 |
| Dividend Yield | N/A | ★ 3.73% |
| EPS Growth | N/A | ★ 4707.69 |
| EPS | N/A | ★ 50.00 |
| Revenue | $36,000.00 | ★ $119,686,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $17,438.13 | N/A |
| P/E Ratio | ★ N/A | $0.34 |
| Revenue Growth | N/A | ★ 1.81 |
| 52 Week Low | $0.39 | $9.76 |
| 52 Week High | $45.00 | $22.79 |
Technical Indicators
Market Signals| Indicator | LYEL | NRC |
|---|---|---|
| Relative Strength Index (RSI) | 40.46 | 58.83 |
| Support Level | $15.82 | $14.78 |
| Resistance Level | $27.30 | $18.29 |
| Average True Range (ATR) | 2.18 | 0.98 |
| MACD | -0.29 | 0.26 |
| Stochastic Oscillator | 27.78 | 75.48 |
Price Performance
Historical ComparisonAbout LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.
About NRC National Research Corporation (Delaware)
National Research Corp is a provider of analytics and insights that facilitate measurement and improvement of the patient and employee experience while also increasing patient engagement and customer loyalty for healthcare providers, payers, and other healthcare organizations. Its portfolio of solutions represents a set of capabilities that individually and collectively provide value to clients. It operates in the United States and Canada, of which key revenue is derived from the United States.